{"id":"videx-ec","safety":{"commonSideEffects":[{"rate":null,"effect":"Pancreatitis"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Lactic acidosis"}]},"_chembl":{"chemblId":"CHEMBL3702597","moleculeType":"Small molecule","molecularWeight":"294.36"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Didanosine (the active ingredient in Videx EC) is phosphorylated intracellularly to didanosine triphosphate, which inhibits HIV reverse transcriptase and terminates viral DNA chain elongation. The extended-release formulation (EC) provides sustained drug levels with once-daily dosing, improving adherence compared to immediate-release formulations.","oneSentence":"Videx EC is a nucleoside reverse transcriptase inhibitor that blocks HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:32.423Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (in combination antiretroviral therapy)"}]},"trialDetails":[{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":3526},{"nctId":"NCT00016718","phase":"PHASE1, PHASE2","title":"Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-08","conditions":"HIV Infections","enrollment":43},{"nctId":"NCT00102960","phase":"PHASE3","title":"Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-07","conditions":"HIV Infections","enrollment":377},{"nctId":"NCT02251873","phase":"PHASE1","title":"Evaluation of the Pharmacokinetic Interaction of Steady State Tipranavir and Ritonavir or Tipranavir and Ritonavir With Single Dose Didanosine in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-09","conditions":"Healthy","enrollment":50},{"nctId":"NCT00142337","phase":"PHASE2","title":"One Month Dual Antiretroviral Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine","status":"COMPLETED","sponsor":"Institut de Recherche pour le Developpement","startDate":"2004-12","conditions":"HIV Infections","enrollment":244},{"nctId":"NCT00002280","phase":"NA","title":"A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00002429","phase":"PHASE3","title":"Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"1999-07","conditions":"HIV Infections","enrollment":500},{"nctId":"NCT00116415","phase":"NA","title":"DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-03","conditions":"HIV Infections, AIDS","enrollment":65},{"nctId":"NCT00002360","phase":"PHASE1","title":"A Study Comparing Two Forms of Didanosine in HIV-infected Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"1999-03","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT00135382","phase":"PHASE3","title":"Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-06","conditions":"HIV Infections","enrollment":254},{"nctId":"NCT00002418","phase":"PHASE2","title":"The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"HIV Infections","enrollment":25},{"nctId":"NCT00002420","phase":"PHASE2","title":"The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"HIV Infections","enrollment":25},{"nctId":"NCT00002168","phase":"NA","title":"A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT00002274","phase":"NA","title":"A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"HIV Infections, Leukoencephalopathy, Progressive Multifocal","enrollment":""},{"nctId":"NCT00002028","phase":"NA","title":"A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00002234","phase":"PHASE2","title":"Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"","conditions":"HIV Infections","enrollment":25},{"nctId":"NCT00008489","phase":"PHASE3","title":"Comparing Side Effects of Two Forms of Videx in HIV-Infected Adults","status":"UNKNOWN","sponsor":"PharmaResearch","startDate":"","conditions":"HIV Infections","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Videx EC","genericName":"Videx EC","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Videx EC is a nucleoside reverse transcriptase inhibitor that blocks HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating. Used for HIV-1 infection (in combination antiretroviral therapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}